Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Mar 1;91(3):497-504.
doi: 10.1016/j.ijrobp.2014.11.012. Epub 2015 Jan 30.

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424

Barbara J Fisher  1 , Chen Hu  2 , David R Macdonald  3 , Glenn J Lesser  4 , Stephen W Coons  5 , David G Brachman  6 , Samuel Ryu  7 , Maria Werner-Wasik  8 , Jean-Paul Bahary  9 , Junfeng Liu  10 , Arnab Chakravarti  11 , Minesh Mehta  12
Affiliations
Clinical Trial

Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424

Barbara J Fisher et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: Radiation Therapy Oncology Group (RTOG) 0424 was a phase 2 study of a high-risk low-grade glioma (LGG) population who were treated with temozolomide (TMZ) and radiation therapy (RT), and outcomes were compared to those of historical controls. This study was designed to detect a 43% increase in median survival time (MST) from 40.5 to 57.9 months and a 20% improvement in 3-year overall survival (OS) rate from 54% to 65% at a 10% significance level (1-sided) and 96% power.

Methods and materials: Patients with LGGs with 3 or more risk factors for recurrence (age ≥40 years, astrocytoma histology, bihemispherical tumor, preoperative tumor diameter of ≥6 cm, or a preoperative neurological function status of >1) were treated with RT (54 Gy in 30 fractions) and concurrent and adjuvant TMZ.

Results: From 2005 to 2009, 129 evaluable patients (75 males and 54 females) were accrued. Median age was 49 years; 91% had a Zubrod score of 0 or 1; and 69%, 25%, and 6% of patients had 3, 4, and 5 risk factors, respectively. Patients had median and minimum follow-up examinations of 4.1 years and 3 years, respectively. The 3-year OS rate was 73.1% (95% confidence interval: 65.3%-80.8%), which was significantly improved compared to that of prespecified historical control values (P<.001). Median survival time has not yet been reached. Three-year progression-free survival was 59.2%. Grades 3 and 4 adverse events occurred in 43% and 10% of patients, respectively. One patient died of herpes encephalitis.

Conclusions: The 3-year OS rate of 73.1% for RTOG 0424 high-risk LGG patients is higher than that reported for historical controls (P<.001) and the study-hypothesized rate of 65%.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: none.

Figures

Fig. 1
Fig. 1
Overall and progression-free survival of RTOG 0424 patients.
Fig. 2
Fig. 2
Overall survival of RTOG 0424 patients reclassified according to the EORTC LGG prognostic model. LGG = low-grade glioma.
See this image and copyright information in PMC

References

    1. Shaw E, Wang M, Coons S, et al. Randomized trial of radiation therapy plus procarbazine, lomustine and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial results of RTOG 9802. J Clin Oncol. 2012;30:3065–3070. - PMC - PubMed
    1. Quinn J, Reardon D, Friedman A, et al. Phase II trial of temozolomide in patients with progressive or recurrent low-grade glioma. J Clin Oncol. 2003;21:646–651. - PubMed
    1. van den Bent M, Chinot O, Boogerd W, et al. EORTC Study 26972: Second line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, CCNU, vincristine) chemotherapy: EORTC phase II study 26. Ann Oncol. 2003;14:599–602. - PubMed
    1. Kesari S, Schiff D, Drappatz J, et al. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009;15:330–337. - PubMed
    1. Kaloshi G, Benouaich-Amiel A, Diakite F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurol. 2007;68:1831–1836. - PubMed

Publication types

MeSH terms